CTOs on the Move

Cure Pharmaceutical

www.curepharmaceutical.com

 
CURE Pharmaceutical is an innovative drug delivery and development company committed to improving drug efficacy, safety and the patient experience through its proprietary drug dosage forms and delivery systems.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Cure Pharmaceutical raised $10M on 11/02/2020

Similar Companies

adMare BioInnovations

Canada’s Global Life Sciences Venture / Partenaire d’affaires en sciences de la vie au Canada #lifesciences #biotech #sante

Families First Pediatrics

With locations in South Jordan & Riverton Utah, our experienced pediatricians & caring team of professionals provides comprehensive care for your children.

Novadoz

Novadoz Pharmaceuticals is a sales and marketing subsidiary for MSN Labs portfolio of finished dosage forms. MSN Labs is a global leader in the development and manufacturing of APIs (active pharmaceutical ingredients).

Vitality Biopharma

Vitality has developed a new class of cannabinoid prodrugs (cannabosides), which enable selective delivery of THC and cannabidiol (CBD) to the gastrointestinal tract. Site-specific delivery could enable potent local therapeutic effects while reducing or avoiding the systemic delivery of THC to the brain. Currently, the psychoactivity of THC limits the dose of cannabinoids that can be used for treatment of pain and inflammation. Studies have shown that the cannabinoid system is a potent mediator of pain relief and inflammation, as studies have shown that cannabinoid drugs can in some cases be far more potent than opiates for pain relief, and far more potent than aspirin or corticosteroids for providing anti-inflammatory effects. For example, cannabinoid drugs have been shown to be nearly 10 times as potent as morphine for neuropathic pain relief. Studies have also shown they can be 20 times as potent as aspirin, and twice as potent as corticosteroids for treating inflammation. But currently, the “elephant in the room” remains, which is that the desired potent effects cannot be achieved when high doses of THC enter the bloodstream and brain. Patients are forced to limit their doses, so targeted administration is critical. Our solution goes to the heart of this issue and offers an alternative means to increase the beneficial dosage, right at the site of disease – where it matters most, and relegates the psychoactive nature of the drug to a manageable side effect.

Sanofi

Sanofi SA is a French multinational pharmaceutical company headquartered in Paris, France, as of 2013 the worlds fifth-largest by prescription sales.